Dementia with Lewy bodies

References cited
Article section 14 of 15.  Previous  Next

By Ann Marie Hake MD

Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009;8(7):613-8.

Barker WW, Luis CA, Kashuba A, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular, and hippocampal sclerosis in the state of Florida brain bank. Alz Dis Assoc Disord 2002;16:203-12.

Baskys A. Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms. J Clin Psychiatry 2004;65(Suppl 11):16-22.

Berg D, Postuma RB, Bloem B, et al. Time to redefine PD? Introductory statement of the MDS task force on the definition of Parkinson’s disease. Mov Disord 2014;29(4):454-62.

Boeve BF. Dementia with Lewy Bodies. Continuum 2004;10(1):81-112.

Boeve BF, Silber MH, Ferman TJ. REM sleep behavior disorder in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 2004;17(3):146-57.

Bonanni L, Perfetti B, Bifolchetti S, et al. Quantitative electroencephalogram utility in predicting conversion of mild cognitive impairment to dementia with Lewy bodies. Neurobiol Aging 2015;36(1):434-45.

Brett FM, Henson C, Staunton H. Familial diffuse Lewy body disease, eye movement abnormalities, and distribution of pathology. Arch Neurol 2002;59(3):464-7.

Claassen DO, Josephs KA, Ahlskog JE, Silber MH, Tippmann-Peikert M, Boeve BF. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology 2010;75(6):494-9.

Coulthart MB, Jansen GH, Olsen E, et al. Diagnostic accuracy of cerebrospinal fluid protein markers for sporadic Creutzfeldt-Jakob disease in Canada: a 6-year prospective study. BMC Neurology 2011;11:133-26.

Del Ser T, Hachinski V, Merskey H, Munoz DG. Clinical and pathologic features of two groups of patients with dementia with Lewy bodies: effect of coexisting Alzheimer-type lesion load. Alzheimer Dis Assoc Disord 2001;15(1):31-44.

Eriksen JL, Dawson TM, Dickson DW, Petrucelli L. Caught in the act: alpha-synuclein is the culprit in Parkinson’s disease. Neuron 2003;40(3):453-6.

Ferman TJ, Smitj GE, Kantarci K, et al. Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies. Neurology 2013;81:2032-8.

Friedman JH, Fernandez HH. Atypical antipsychotics in Parkinson-sensitive populations. J Geriatr Psychiatry Neurol 2002;15(3):156-70.

Gallagher-Thompson D, Coon DW. Evidence-based psychological treatments for distress in family caregivers of older adults. Psychol Aging 2007;22(1):37-51.

Galvin JE, Lee SL, Perry A, Havlioglu N, McKeel DW, Morris JC. Familial dementia with Lewy bodies: clinicopathologic analysis of two kindreds. Neurology 2002;59(7):1079-82.

Goker-Alpan O, Stubblefield BK, Giasson BI, Sidransky E. Glucocerebrosidase is present in alpha-synuclein inclusions in Lewy body disorders. Acta Neuropathol 2010;120(5):641-9.

Graff-Radford J, Murray ME, Lowe VJ, et al. Dementia with Lewy bodies: basis of cingulate island sign. Neurology 2014;83:801-9.

Guyant-Marechal I, Berger E, Laquerrière A, et al. Intrafamilial diversity of phenotype associated with app duplication. Neurology 2008;71(23):1925-6.

Hansen L, Salmon D, Galasko D, et al. The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology 1990;40(1):1-8.

Harding AJ, Das A, Kril JJ, Brooks WS, Duffy D, Halliday GM. Identification of families with cortical Lewy body disease. Am J Med Genet B Neuropsychiatr Genet 2004;128(1):118-22.

Holdorff B. Friedrich Heinrich Lewy (1885-1950) and his work. J Hist Neurosci 2002;11(1):19-28.

Irwin DJ, White MT, Toledo JB, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol. 2012;72(4):587-98.

Jellinger KA, Wenning GK, Seppi K. Predictors of survival in dementia with Lewy bodies and Parkinson dementia. Neurodegener Dis 2007;4(6):428-30.

Khachaturian ZS. Alzheimer’s disease: progress toward untangling the mystery. In: Appel SH, editor. Current neurology, Vol 15. St. Louis: Mosby, 1995:193-210.

Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56(9):1143-53.

Koeppe RA, Gilman S, Junck L, Wernette K, Frey KA. Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+)-[11C]dihydrotetrabenazine positron emission tomography. Alzheimers Dement 2008;4(1 Suppl 1):S67-76.

Kosaka K. Diffuse Lewy body disease. Neuropathology 2000;20(Suppl):S73-8.

Larsson V, Aarsland D, Ballard C, Minthon L, Londos E. The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. Int J Geriatr Psychiatry 2010;25(10):1030-8.

Lee DR, McKeith I, Mosimann U, Ghosh-Nodyal A, Thomas AJ. Examining carer stress in dementia: the role of subtype diagnosis and neuropsychiatric symptoms. Int J Geriatr Psychiatry 2012. doi: 10.1002/gps.3799.

Leggett AN, Zarit S, Taylor A, Galvin JE. Stress and burden among caregivers of patients with Lewy body dementia. Gerontologist 2011;51(1):76-85.

Leverenz JB, Fishel MA, Peskind ER, et al. Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype. Arch Neurol 2006;63(3):370-6.

Lewy FH. Paralysis agitans: pathologische Anatomie. In: Lewandowsky M, editor. Handbuch der Neurologie, Vol 3. Berlin: Springer, 1912:920-33.

Lingler JH, Kaufer DI. Cognitive and motor symptoms in dementia: focus on dementia with Lewy bodies. J Am Acad Nurse Pract. 2002;14(9):398-404; quiz 405-7.

Logsdon RG, McCurry SM, Teri L. Evidence-based psychological treatments for disruptive behaviors in individuals with dementia. Psychol Aging 2007;22(1):28-36.

Lucetti C, Logi C, Del Dotto P, et al. Levodopa response in dementia with Lewy bodies: a 1-year follow-up study. Parkinsonism Relat Disord 2010;16(8):522-6.

McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356(9247):2031-6.

McKeith I, O'Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007;6(4):305-13.

McKeith IG. Dementia with Lewy bodies. Br J Psychiatry 2002;180:144-7.

McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65(12):1863-72.**

McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47(5):1113-24.

McKeith IG, Perry EK, Perry RH. Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology 1999;53(5):902-5.

Metzler M, Duerr S, Granata R, Krismer F, Robertson D, Wenning GK. Neurogenic orthostatic hypotension: pathophysiology, evaluation, and management. J Neurol 2013;260:2212-9.

Miyasaki JM, Shannon K, Voon V, et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66(7):996-1002.

Mizukami K, Homma T, Aonuma K, et al. Decreased ventilatory response to hypercapnia in dementia with Lewy bodies. Ann Neurol 2009;65:614-7.

Molloy S, McKeith IG, O’Brien JT, Burn DJ. The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2005;76(9):1200-3.

Mori E, Ikeda M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol 2012;72:41-52.

Nelson PT, Jicha GA, Kryscio RJ, et al. Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurol 2010;257(3);359-66.

Ohara K, Takauchi S, Kokai M, Morimura Y, Nakajima T, Morita Y. Familial dementia with Lewy bodies (DLB). Clin Neuropathol 1999;18(5):232-9.

Ohtake H, Limprasert P, Fan Y, et al. Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology 2004;63(5):805-11.

Okazaki H, Lipkin LE, Aronson SM. Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J Neuropathol Exp Neurol 1961;20:237-44.

Ornstein K, Gaugler JE, Devenand DP, Scarmeas N, Zhu C, Stern Y. The differential impact of unique behavioral and psychological symptoms for the dementia caregiver: how and why do patients’ individual symptom clusters impact caregiver depressive symptoms? Am J Geriatr Psychiatry 2013;21(12):1277-86.

Perry RH, Irving D, Blessed G, Perry EK, Fairbairn AF. Senile dementia of Lewy body type and spectrum of Lewy body disease. Lancet 1989;1(8646):1088.

Raciti L, Nicoletti A, Le Pira F, et al. Presenilin-2 gene mutation presenting as Lewy Body dementia? Neurol Sci 2011;32(3):533-4.

Rongve A, Vossius C, Nore S, Testad I, Aasland D. Time until nursing home admission in people with mild dementia: comparison of dementia with Lewy bodies and Alzheimer’s dementia. Int J Geriatr Psychiatry 2014;29(4):392-8.

Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007;69:2197-204.

Schneider JA, Arvanitakis Z, Yu L, Boyle PA, Leurgans SE, Bennett DA. Cognitive impairment, decline, and fluctuations in older community-dwelling subjects with Lewy bodies. Brain 2012;135:3005-14.

Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294(15):1934-43.

Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006;14(3):191-210.

Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997;388(6645):839-40.

Sweeney PJ, Lloyd MF, Daroff RB. What's in a name? Dr. Lewey and the Lewy body. Neurology 1997;49(2):629-30.

Tateno M, Kobayashi S, Shirasaka T, et al. Comparison of the usefulness of brain perfusion SPECT and MIBG myocardial scintigraphy for the diagnosis of dementia with Lewy bodies. Dement Geriatr Cogn Discord 2008;26(5):453-7.

Treglia G, Cason E, Gabellini A, Giordan A, Fagioli G. Recent developments in innervation imaging using iodine-123-metaiodobenzylguanidine scintigraphy in Lewy body diseases. Neurol Sci 2010;31:417-22.

Tretiakoff C. Contribution a l’etude de l’anatomie pathologique du locus niger de Soemmering avec quelques deductions relatives a la pathogenie des troubles du tonus musculaire et de la maladie de Parkinson. Paris: Paris, 1919.

Tsuang DW, DiGiacomo L, Bird TD. Familial occurrence of dementia with Lewy bodies. Am J Geriatr Psychiatry 2004;12(2):179-88.

Vander Borght T, Minoshima S, Giordani B, et al. Cerebral metabolic differences in Parkinson’s and Alzheimer’s diseases matched for dementia severity. J Nucl Med 1997;38:797-802.

Varanese S, Perfetti B, Gilbert-Wolf R, Thomas A, Onofrj M, Di Rocco A. Modafinil and armodafinil improve attention and global mental status in Lewy bodies disorders: preliminary evidence. Int J Geriatr Psychiatry 2013;28(10):1095-7.

Wakabayashi K, Hayashi S, Ishikawa A, et al. Autosomal dominant diffuse Lewy body disease. Acta Neuropathol (Berl) 1998;96(2):207-10.

Whitwell JL, Weigand SD, Shiung MM, et al. Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. Brain 2007;130(Pt 3):708-19.

Williams MM, Xiong C, Morris JC, Galvin JE. Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease. Neurology 2006;67(11):1935-41.

Zhang W, Wang T, Pei Z, et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 2005;19(6):533-42.

**References especially recommended by the author or editor for general reading.

In This Article

Historical note and nomenclature
Clinical manifestations
Clinical vignette
Pathogenesis and pathophysiology
Differential diagnosis
Diagnostic workup
Prognosis and complications
References cited